New Clinical Trials
BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer
RU011201l: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
RU0214071: Regorafenib Dose Optimization Stuy (ReDos): A Phase II Randomized Study of Lower Dose Regorafenib compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer
EA6134: Advanced Mutant Melanoma - A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma.
C-13 ARGO: A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
RADIUS X: An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Frms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia who are eligible for standard induction and consolidation chemotherapy